Nikesh Shah, MD @TheOncDoc

Hematologist/Oncologist @TGHCares Cancer Institute. Trained @MoffittNews, @EmoryDeptofMed, @umiamimedicine. Interest in lymphoma. All tweets my own. Tampa, FL Joined September 2019

Tweets

196
Followers

329
Following

170
Likes

559

Nikesh Shah, MD @TheOncDoc

2 years ago

Had a blast discussing CAR-T and bispecifics in lymphoma with Alan Kerr! Excited to bring these game changing therapies to our patients @TGHCares

Tampa General Hospital @TGHCares

2 years ago

Had a blast discussing CAR-T and bispecifics in lymphoma with Alan Kerr! Excited to bring these game changing therapies to our patients @TGHCares

1 2 4 1K 0

Download Image

0 0 10 588 1

Interesting study on burnout in hem/onc - working with APPs (not surprising!) and being young are protective but being female 💆🏻‍♀️ and RVU-only based compensation increase odds for burnout. ashpublications.org/bloodadvances/…

3 26 64 27K 13

Nikesh Shah, MD @TheOncDoc

2 years ago

Glofitamab just approved in r/r DLBCL after 2 lines. Also requires hospitalization for full dose like Epco. Biggest difference is finite duration. fda.gov/drugs/drug-app…

1 0 2 387 0

Nikesh Shah, MD @TheOncDoc

2 years ago

Epcoritamab just approved for r/r DLBCL! Very exciting to see how this will be implemented in the community prnewswire.com/news-releases/…

0 0 6 544 1

Nikesh Shah, MD @TheOncDoc

2 years ago

Incredibly humbling and inspiring to present our work on TP53 altered mantle cell lymphoma at the @lymphoma MCL Consortium to giants in the field who literally defined the disease and how we manage it to this day. Fantastic conference chaired by Dr. Eduardo Sotomayor #lymsm

2 2 29 2K 2

Download Image

Nikesh Shah, MD @TheOncDoc

2 years ago

Grateful to help grow the lymphoma program and build a mantle cell lymphoma center of excellence under the leadership of Dr. Eduardo Sotomayor @TGHCares Cancer Institute! tgh.org/news/tgh-press… #lymsm

4 1 22 1K 1

Nikesh Shah, MD @TheOncDoc

2 years ago

Pola-R-CHP approved for DLBCL or HGBCL with IPI 2 or higher based on POLARIX data. Interesting since subgroup analysis showed less benefit for IPI 2, GCB, and double hit (of course not powered for this). Will you use universally for this population? Longer fu is crucial #lymsm

0 0 2 387 0

Download Image

Nikesh Shah, MD @TheOncDoc

3 years ago

Congratulations! Very well deserved!

Moffitt Hematology/Oncology Fellowship @MoffittHemOnc

3 years ago

Congratulations! Very well deserved!

0 3 29 3K 0

0 0 5 508 0

Mark Lewis, MD, FASCO @marklewismd

3 years ago

An absolutely maddening, but telling excerpt from the @propublica report on UnitedHealthcare denying a patient's much-needed ulcerative colitis treatment 👇 Often, the arbiters of what is "clinically appropriate" don't have subspecialty expertise or up-to-date practice patterns!

6 13 87 12K 2

Download Image

Nikesh Shah, MD @TheOncDoc

3 years ago

Pirtobrutinib FDA approved for relapsed/refractory mantle cell lymphoma after prior btk inhibitor! #lymsm fda.gov/drugs/resource…

0 0 5 548 0

Nikesh Shah, MD @TheOncDoc

3 years ago

Don't forget to check out the excellent ASH educational series. Nice to have everything in one place to reference. Wonderful reviews by @anitajkumarMD and @ChrisRFlowersMD, among others ashpublications.org/hematology/iss…

1 2 11 3K 2

Hagop Kantarjian,MD @DrHKantarjian

3 years ago

Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL. Jabbour, Short, Kantarjian of @MDAndersonNews #Leukemia authors.elsevier.com/a/1g5k18MsWYC4… via @TheLancetHaem #leusm

9 125 372 0 23

Download Image

Gaurav Goyal @GauravGoyalMD

3 years ago

BREAKING NEWS!🔥 FDA approves cobimetinib for histiocytic neoplasms! This is a huge victory for this underserved population, and highlights that clinical trials are feasible for ultra-rare diseases. bit.ly/3Dn4Lwk @Histiocytosis @ECDGA @MSK_Histio @HistiocyteSoc